- Poster presentation
- Open Access
- Published:
Two cases of multiple-drug-resistant adult-onset Still's disease treated successfully with tocilizumab - the relationship between interleukin 6 and 18
Arthritis Research & Therapy volume 14, Article number: P62 (2012)
Background
Adult-onset Still's disease (AOSD) is an inflammatory disease of unknown cause characterized by a high spiking fever, arthritis and evanescent rash. The mainstay of treatment is glucocorticoids with or without immunosuppressants. Recently, biologics such as anti-tumor necrosis factor (TNF) antibodies have also been tried in certain refractory cases.
Results
We have had two cases of AOSD which were treated successfully with anti-interleukin (IL-) 6-receptor antibody, tocilizumab (TOC). (Case 1) A 36-year-old woman who was diagnosed 8 years previously, and had been treated with various DMARDs plus etanercept (ETA) or adalimumab, presented with a high spiky fever and elevated liver enzymes. After excluding infection, she was treated with TOC. (Case 2) A 26-year-old man with new-onset AOSD, which was shown to be resistant to multiple immunosuppressants including infliximab and ETA, was treated with TOC starting 7 months after the diagnosis. In both cases, serum IL-18 was extremely high, and TOC promptly improved clinical symptoms and liver function. The high level of serum ferritin also became normalized. Interestingly, especially in case 2, the level of IL-18 remained high after the administration of TOC, suggesting that IL-18 is located either upstream of, or at the same level as, IL-6 in the pathogenesis of AOSD. Next, we cultured human monocytes derived from healthy controls with or without the presence of IL-6 and/or IL-18 in vitro. The level of ferritin in the supernatant was significantly increased only when both IL-6 and IL-18 were added, indicating that IL-6 and IL-18 have a synergistic effect on the production of ferritin (Figure 1).
The level of ferritin in the supernatant of monocytes cultured with or without the presence of IL-6 and/or IL-18 (10 ng/mL each)
Conclusion
TOC can be a first-line biologic applicable against multiple-drug-resistant AOSD. If an IL-18 blocker is developed, however, it may be even more beneficial in that it may block the cascade of inflammation at a point further upstream.
Author information
Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sato, K., Yamamoto, A., Yoshida, Y. et al. Two cases of multiple-drug-resistant adult-onset Still's disease treated successfully with tocilizumab - the relationship between interleukin 6 and 18. Arthritis Res Ther 14, P62 (2012). https://doi.org/10.1186/ar3663
Published:
Keywords
- Arthritis
- Glucocorticoid
- Infliximab
- Ferritin
- Etanercept
